Moderna to supply extra 4.5M doses of Omicron-targeting booster to Canada, swap Spikevax with bivalent shot
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) said the Canadian government exercised its option to buy an additional 4.5M doses of an Omicron-containing bivalent vaccine booster shot, in addition to moving forward the scheduled delivery of 1.5M doses of the bivalent vaccine to 2022 from 2023.

The company's bivalent booster vaccine targets the original COVID-19 strain and the Omicron variant. The redesigned booster was approved in the U.K. earlier this month.
Moderna and Canada also agreed to convert 6M doses of COVID-19 vaccine Spikevax (mRNA-1273) to an Omicron-containing bivalent vaccine, the company said in an Aug. 22 press release.
Moderna noted that the agreement is subject to regulatory approval of the Omicron-containing bivalent booster by Health Canada, with doses scheduled for delivery in 2022.
MRNA -1.84% to $143.41 premarket Aug. 22